<![CDATA[Organon & Co. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=37833>Sat, 13 Jun 2026 23:13:33 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Organon to Present New Research on Access and Value at ISPOR 2026]]>https://www.newswire.co.kr/newsRead.php?no=1034800Tue, 19 May 2026 16:00:00 +0900<![CDATA[오가논, ISPOR 2026에서 접근성 및 가치에 관한 새로운 연구 발표 예정]]>https://www.newswire.co.kr/newsRead.php?no=1034801Tue, 19 May 2026 16:00:00 +0900<![CDATA[Sun Pharma signs Definitive Agreement to Acquire Organon]]>https://www.newswire.co.kr/newsRead.php?no=1033341Tue, 28 Apr 2026 15:30:00 +0900<![CDATA[선 파마, 오가논 인수 최종 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1033342Tue, 28 Apr 2026 15:30:00 +0900<![CDATA[Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device]]>https://www.newswire.co.kr/newsRead.php?no=1029135Tue, 24 Feb 2026 16:10:00 +0900<![CDATA[오가논, 세벨라 파마슈티컬스의 비호르몬 자궁 내 피임장치 ‘미우델라’ 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=1029136Tue, 24 Feb 2026 16:10:00 +0900<![CDATA[Organon Completes Divestiture of JADA® System to Laborie]]>https://www.newswire.co.kr/newsRead.php?no=1027883Fri, 30 Jan 2026 10:50:00 +0900<![CDATA[오가논 ‘제이다 시스템’ 라보리에 매각 완료]]>https://www.newswire.co.kr/newsRead.php?no=1027885Fri, 30 Jan 2026 10:50:00 +0900<![CDATA[Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US]]>https://www.newswire.co.kr/newsRead.php?no=1023327Tue, 18 Nov 2025 15:10:00 +0900<![CDATA[헨리우스와 오가논, 미국 최초 퍼제타 바이오시밀러 포허디의 FDA 승인 발표]]>https://www.newswire.co.kr/newsRead.php?no=1023328Tue, 18 Nov 2025 15:10:00 +0900<![CDATA[Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie]]>https://www.newswire.co.kr/newsRead.php?no=1022583Mon, 10 Nov 2025 10:15:00 +0900<![CDATA[오가논, 자다 시스템을 라보리에 최대 4억6500만달러에 매각하는 계약 체결 발표]]>https://www.newswire.co.kr/newsRead.php?no=1022587Mon, 10 Nov 2025 10:15:00 +0900<![CDATA[US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection]]>https://www.newswire.co.kr/newsRead.php?no=1012225Fri, 30 May 2025 10:40:00 +0900<![CDATA[미국 식품의약국, 삼성바이오에피스와 오가논의 하드리마 주사제에 상호교환성 지정 승인]]>https://www.newswire.co.kr/newsRead.php?no=1012226Fri, 30 May 2025 10:20:00 +0900<![CDATA[European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11]]>https://www.newswire.co.kr/newsRead.php?no=1009310Sun, 13 Apr 2025 10:25:00 +0900<![CDATA[유럽의약품청(EMA), 헨리우스와 오가논의 Perjeta®(퍼투주맙) 바이오시밀러 후보물질 HLX11 신청 검증 완료]]>https://www.newswire.co.kr/newsRead.php?no=1009311Sun, 13 Apr 2025 10:25:00 +0900<![CDATA[US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)]]>https://www.newswire.co.kr/newsRead.php?no=999754Thu, 31 Oct 2024 09:13:25 +0900<![CDATA[Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%]]>https://www.newswire.co.kr/newsRead.php?no=997121Fri, 20 Sep 2024 14:20:00 +0900<![CDATA[오가논, 더마반트 인수… 혁신적 피부과 치료제 ‘VTAMA® 크림’과 ‘1%’ 포함]]>https://www.newswire.co.kr/newsRead.php?no=997123Fri, 20 Sep 2024 14:20:00 +0900<![CDATA[Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets]]>https://www.newswire.co.kr/newsRead.php?no=995347Wed, 21 Aug 2024 14:45:00 +0900<![CDATA[오가논-릴리, 편두통 상용화 계약을 11개 추가 시장으로 확대]]>https://www.newswire.co.kr/newsRead.php?no=995367Wed, 21 Aug 2024 14:45:00 +0900<![CDATA[European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14]]>https://www.newswire.co.kr/newsRead.php?no=990382Sun, 26 May 2024 10:55:00 +0900<![CDATA[유럽의약품청, 프롤리아® 및 엑스게바® 바이오시밀러 후보물질 HLX14에 대한 헨리우스 및 오가논의 제출서류 검증]]>https://www.newswire.co.kr/newsRead.php?no=990383Sun, 26 May 2024 10:55:00 +0900<![CDATA[Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints]]>https://www.newswire.co.kr/newsRead.php?no=987499Tue, 09 Apr 2024 11:30:00 +0900<![CDATA[프롤리아®·엑스게바® 바이오시밀러 후보물질 HLX14, 임상 3상 비교 임상시험서 1차 평가변수 충족]]>https://www.newswire.co.kr/newsRead.php?no=987507Tue, 09 Apr 2024 11:30:00 +0900